New FDA guidance on interchangeable biosimilar labeling heads to White House for review

The FDA has submitted a draft guidance focused on the labeling of interchangeable biosimilar products to the White House for review, which would fulfill a Biosimilar User Fee Act (BsUFA III) commitment. While the exact contents of this guidance are unclear, prior FDA labeling guidance may offer some clues as to FDA’s approach.

Regulatory Context: Biosimilars and Interchangeability

The FDA was first authorized to develop a pathway for the approval of biosimilar products in 2010 under the Biologics Price Competition and Innovation (BPCI) Act. Biosimilars are biological products that are highly similar to a previously approved biological product and have “no clinically meaningful” differences relative to the original reference product.

Fill out the form to read the full article.

Copy link
Powered by Social Snap